EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations

Almudena Testera-Montes, Laura Zubiaga-Fernandez, Carlos J Aranda iD, Irene Garcia-Esteban, Trinidad Ilda Gaitan-Nievas, Dulce Sanchez-Torralvo, Cristobalina Mayorga iD, Maria J Torres iD, Ibon Eguiluz-Gracia iD, Carmen Rondon iD

Allergy · 2026

DOI: 10.1111/all.70153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2026. Verfasst von Almudena Testera-Montes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Rhinitis, Allergic, Asthma, Allergens. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Commission, Instituto de Salud Carlos III, Consejería de Salud y Familias, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials (CTs) have shown that allergen immunotherapy (AIT) is effective for local allergic rhinitis (LAR) while treatment is ongoing. However, its long‐term effects remain unknown. This study investigates the long‐term clinical and preventive effect of AIT in responder LAR patients.

Methods

LAR patients obtaining a clinical benefit from 1‐year CT of subcutaneous AIT were enrolled in this 10‐year follow‐up study (AIT cohort). All completed a full 3‐year AIT course and were followed for additional 7 years. A matched group of LAR patients who did not receive AIT (non‐AIT cohort) was followed over the same period. Primary outcomes included nasal‐ocular symptom scores (visual analogue scale, VAS), reliever medication use and medication‐free days (MFD). Secondary outcomes were asthma incidence, asthma control (asthma control test, ACT), lung function (FEV 1 ), quality of life (QoL), emergency visits, new sensitizations detected by nasal allergen challenge (NAC), and the analysis of the minimal clinically important difference (MCID). Assessments were conducted at baseline and at years 1, 3, 5, 7, and 10.

Results

Sixty‐six patients were included (AIT n = 32; non‐AIT n = 34). The AIT cohort showed a sustained reduction in nasal‐ocular symptoms from year 1 ( p < 0.001) and significantly more MFD from year 3 ( p < 0.001). Asthma developed in 40.7% of non‐AIT vs. 8.0% of AIT patients ( p = 0.021). New sensitizations occurred in 38.2% of non‐AIT and 6.3% of AIT patients ( p = 0.002). FEV 1 improved in the AIT cohort and declined in non‐AIT ( p < 0.001). QoL and emergency visits also favored AIT.

Conclusion

AIT induces a sustained clinical improvement and prevents the onset of asthma and local sensitizations in responder LAR patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicRhinitis, AllergicAsthmaAllergensHumansFemaleMaleAdultTreatment OutcomeMiddle AgedQuality of LifeFollow-Up Studies

Stichwörter der Autor:innen

allergen immunotherapyasthmalocal allergic rhinitislong‐term effectprevention

Substanzen

Allergens

Autor:innen und Institutionen

  • Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain.
  • Allergy Group, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Malaga, Spain.
  • Department of Medicine and Dermatology, University of Malaga, Malaga, Spain.

ORCID-Profile: Carlos J Aranda, Cristobalina Mayorga, Maria J Torres, Ibon Eguiluz-Gracia, Carmen Rondon

Förderung

  • European Commission
  • Instituto de Salud Carlos III
  • Consejería de Salud y Familias, Junta de Andalucía
  • Universidad de Málaga/CBUA
  • Universidad de Málaga

Zitieren

APA

Testera-Montes, A., Zubiaga-Fernandez, L., Aranda, C. J., Garcia-Esteban, I., Gaitan-Nievas, T. I., Sanchez-Torralvo, D., Mayorga, C., Torres, M. J., Eguiluz-Gracia, I., & Rondon, C. (2026). Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations. Allergy. https://doi.org/10.1111/all.70153

Vancouver

Testera-Montes A, Zubiaga-Fernandez L, Aranda CJ, Garcia-Esteban I, Gaitan-Nievas TI, Sanchez-Torralvo D, et al. Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations. Allergy. 2026. doi:10.1111/all.70153

BibTeX
@article{TesteraMontes2026,
  author = {Testera-Montes, Almudena and Zubiaga-Fernandez, Laura and Aranda, Carlos J and Garcia-Esteban, Irene and Gaitan-Nievas, Trinidad Ilda and Sanchez-Torralvo, Dulce and Mayorga, Cristobalina and Torres, Maria J and Eguiluz-Gracia, Ibon and Rondon, Carmen},
  title = {Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70153}
}
Kostenlos starten →